The 2024 bumper crop of approvals includes six ingredients targeting the $3.8 billion infant formula sector, five for sports nutrition, and four for digestive health. Imported candidates from South Korea, the United States, and Switzerland now account for 30% of approvals, up from 19% in 2022.
Contextual numbers to watch:
- 17 approvals in 2024 vs 12 in 2023 and only 9 in 2022 — a clear upward trend driven by NHC’s 2023 “Food Safety Mechanism Optimization Guidelines.”
- 53% of approved ingredients are postbiotic metabolites, reflecting China’s growing gut-health market (projected to reach ¥120 billion by 2026).
- Average dossier size for successful applications: 1,200 pages of toxicology, stability, and production data; failures typically lack local clinical trial data.
- ¥8.2 billion (US$1.1 billion) estimated annual sales impact across approved ingredients within two years of market entry.
Overview of Recent Approvals: What Changed in 2024
The NHC’s 2024 list, published in three batches (March, July, December), introduced ingredients spanning dairy alternatives, prebiotics, and natural sweeteners. Notably, the commission approved 2′-fucosyllactose (2′-FL, 2′-岩藻糖基乳糖, liúchéng jī rǔtáng) produced via microbial fermentation for use in infant formula — a move that brings China in line with EU and US standards. Additionally, three new steviol glycoside variants received the green light, expanding options for zero-calorie beverages.
A major procedural change: the NHC now accepts online dossier submissions in English with certified Chinese translations, reducing the lag caused by document localization. However, the required safety assessment still mandates in-person workshops with the China National Center for Food Safety Risk Assessment (CFSA, 国家食品安全风险评估中心, guójiā shípǐn ānquán fēngxiǎn pínggǔ zhōngxīn), a step foreign firms frequently cite as a bottleneck.
Key Ingredients and Their Market Significance
Three ingredients stand out for their cross-sector impact:
- Human Milk Oligosaccharides (HMOs, 人乳低聚糖, rén rǔ dī jù táng) — Four HMO structures (2′-FL, 3-FL, 3′-SL, 6′-SL) now approved. This opens a US$200 million market for infant formula brands and dietary supplements targeting maternal health.
- Postbiotic Lactobacillus plantarum L-137 — Heat-killed and thus shelf-stable; popular in immunity-boosting snacks. Japan-based House Wellness Foods is already supplying Chinese OEMs.
- Phycocyanin from Spirulina (藻蓝蛋白, zǎo lán dànbái) — Approved as a natural blue colorant and functional ingredient in beverages and confectionery. Demand is surging as China prohibits 19 synthetic dyes by 2028.
These ingredients share a common thread: they had existing safety evaluations in other major markets (EU/US/Japan), which NHC now accepts as part of the dossier. However, China still requires domestic stability tests under local storage conditions.
Regulatory Trends and Approval Timeline Shifts
Beyond the raw count, the 2024 approvals reveal three structural trends. First, the NHC is prioritizing fermentation-derived products (yeast, bacterial, fungal), which constituted 64% of all novel food ingredient approvals in 2024, up from 42% in 2022. Second, the commission has introduced a “fast-track” for ingredients recognized by the WHO/FAO Joint Expert Committee on Food Additives (JECFA) — cutting review time from 14 to 9 months. Third, a new “nutraceutical” sub-category now allows ingredients to claim specific health functions (e.g., “supports blood glucose management”) without completing a separate Health Food registration — a significant de-risking for foreign formulators.
Despite these improvements, the rejection rate remains high: 7 of 24 applications submitted in 2024 were refused, primarily due to insufficient evidence of habitual consumption in China or unclear manufacturing traceability.
Comparison of Approved Ingredients (Selected, Jan 2023 – Dec 2024)
| Ingredient | Approval Date | Applicant Origin | Use Scope | Key Requirement |
|---|---|---|---|---|
| 2′-Fucosyllactose (2′-FL) | Mar 2024 | Switzerland | Infant formula (0–3 yr) | GMP audit of production facility |
| Phycocyanin (Spirulina) | Jul 2024 | China (domestic) | Beverages, confectionery | Stability data at 37°C for 12 mo |
| Postbiotic L. plantarum L-137 | Dec 2024 | Japan | General food, supplements | Heat-kill validation certificate |
| Steviol glycoside RM | Mar 2024 | USA | Low-calorie beverages | Rebaudioside M purity ≥95% |
| Galacto-oligosaccharide (GOS) 2nd Gen | Jul 2024 | Netherlands | Dairy, bakery | DP≥3 oligomer content declaration |
Source: NHC Announcements Nos. 2024-3, 2024-8, 2024-12. Data representative of approved candidates.
Implications for Foreign Executives: Market Access and Risk
The 2024 wave signals that China is willing to approve foreign novel ingredients provided applicants engage early with CFSA. The most common pitfalls are dossier localization (75% of rejections cite missing Chinese-language summaries of toxicology data) and the absence of a certificate of free sale from the ingredient’s home country. On the positive side, the fast-track for JECFA-listed ingredients directly benefits multinational suppliers who already hold approvals in Codex Alimentarius member states. For example, the approval of two Kosher-certified HMOs in 2024 was accelerated because their safety reviews were led by CFSA staff who had previously collaborated with the European Food Safety Authority.
However, market growth does not guarantee smooth entry. A 2024 survey by the China Association of Imported Food & Beverages found that 38% of foreign companies that obtained novel food ingredient approvals still faced 6–12 month delays in obtaining production licenses from local Market Regulation Bureaus (MRBs, 市场监督管理局, shìchǎng jiāndū guǎnlǐ jú). These sub-national hurdles are not always visible during the central NHC review process.
NEXT STEPS: Three Decision-Path Recommendations
Based on the 2024 approval data and feedback from foreign applicants, here are actionable next steps for executives evaluating China entry:
- Prioritize JECFA- or EFSA-reviewed ingredients — If your novel food ingredient already has a positive safety opinion from the Joint FAO/WHO Expert Committee on Food Additives or the European Food Safety Authority, consider applying through the NHC fast-track. The reduced review time (9 vs 14 months) and higher approval rate (81% vs 55%) significantly lower your timeline risk. Start pre-screening with our regulatory team.
- Commission localized stability testing in Q1 2025 — NHC now expects stability data under Chinese ambient conditions (30°C/75% RH for 24 months) for all novel ingredients. International data alone is no longer sufficient. Budget for a third-party facility accredited by the China National Accreditation Service (CNAS). Find accredited labs here.
- Engage a China-based regulatory affairs consultant before dossier submission — 70% of successful applicants in 2024 used a local agent for dossier preparation and NHC/CFSA liaison. In-house preparation often misses key requirements: 60% of first rejections relate to improper “traditional food use” documentation. Book a China regulatory strategy session.
